- Home
- FSP vs LXEO Comparison
FSP vs LXEO Comparison
Compare FSP & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSP | LXEO |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.3M | 663.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | FSP | LXEO |
|---|---|---|
| Price | $0.98 | $9.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.22 |
| AVG Volume (30 Days) | 684.6K | ★ 995.5K |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,497,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $0.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $1.45 |
| 52 Week High | $2.21 | $10.38 |
Technical Indicators
Market Signals| Indicator | FSP | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 57.77 |
| Support Level | $0.90 | $9.12 |
| Resistance Level | $0.99 | $9.71 |
| Average True Range (ATR) | 0.05 | 0.60 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 47.04 | 81.77 |
Price Performance
Historical ComparisonAbout FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.